Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
Antiangiogenic therapy is a valuable new approach in the treatment of breast cancer. Response rates ranging from 6.7% to 54% were reported using Bevacizumab (Avastin), anti-vascular endothelial growth factor, with chemotherapy. We report the first case of a patient, with a highly vascular breast cancer that recurred locally while on treatment with paclitaxel and trastuzumab combination, but showed complete clinical and pathological regression upon the addition of bevacizumab therapy to the same combination.
Farhat
Mirna H
MH
American University of Beirut-Medical center, Internal medicine-Division of Hematology-Oncology, Riad El - Solh, Beirut-Lebanon. bellanotchi@hotmail.com
El-Saghir
Nagi S
NS
Shamseddine
Ali I
AI
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D015411:Mastectomy, Modified Radical; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D000068878:Trastuzumab
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D000068258:Bevacizumab; D000068878:Trastuzumab; D017239:Paclitaxel